Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dual-Force
- Development stage
- Unknown
- Lead developer
- ImmuCell
- Modality
- Antibody-Based Therapeutics
- Administration
- Oral
01
Overview
Dual-Force is a veterinary biologic, specifically an oral gel formulation, developed and manufactured by ImmuCell Corporation. It is designed to provide immediate passive immunity to newborn beef and dairy calves against bacterial and viral scours. The product contains bovine antibodies derived from 100% dried colostrum, targeting K99+ Escherichia coli and bovine coronavirus, two major causes of calf scours. Administered shortly after birth, it helps reduce mortality and morbidity by neutralizing these pathogens.
- Brand names
- Dual-ForceFirst Defense Dual-ForceDual-Force First Defense Gel
02
Targets
Bovine coronavirus surface antigensF5 (Coagulation Factor V)
Beyond the preview
Go deeper on Dual-Force.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dual-Force.